SREBF2: A Non-Coding RNA Molecule with Potential as A Drug Target

Target Name: SREBF2

NCBI ID: G6721

SREBF2

SREBF2: A Non-Coding RNA Molecule with Potential as A Drug Target

SREBF2 (bHLHd2) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and function have made it an attractive target for researchers to study and develop new treatments.

SREBF2 is a RNA molecule that is found in various tissues throughout the body, including the brain, heart, and liver. It is composed of 257 amino acid residues and has a molecular weight of 31 kDa. SREBF2 is a non-coding RNA molecule, which means that it does not have a functional RNA molecule, but it can interact with other molecules to regulate gene expression.

One of the key features of SREBF2 is its ability to interact with the protein p16INK4a. p16INK4a is a transcription factor that plays a role in cell proliferation and has been linked to various diseases, including cancer. SREBF2 has been shown to physically interact with p16INK4a and can modulate its activity. This interaction between SREBF2 and p16INK4a suggests that SREBF2 may be a useful drug target for cancer treatment.

Another potential mechanism by which SREBF2 may be involved in cancer is its role in the regulation of cell apoptosis. SREBF2 has been shown to be involved in the apoptosis signaling pathway, which is a critical mechanism that helps cells eliminate themselves when they are no longer needed . SREBF2 has been shown to promote the expression of genes that are involved in cell apoptosis, which suggests that it may play a negative role in cancer development.

In addition to its potential role in cancer, SREBF2 has also been studied for its potential as a drug target for other diseases. For example, SREBF2 has been shown to be involved in the regulation of inflammation, which is a critical aspect of many diseases, including cancer. SREBF2 has been shown to interact with the protein NF-kappa-B, which is involved in inflammation regulation. This interaction suggests that SREBF2 may be a useful target for drugs that are designed to treat inflammatory diseases, including cancer.

Another potential application of SREBF2 as a drug target is its role in the regulation of cell signaling pathways. SREBF2 has been shown to be involved in the regulation of several signaling pathways, including the TGF-β pathway and the Wnt pathway. These pathways are involved in a wide range of cellular processes, including cell growth, differentiation, and survival. SREBF2 has been shown to play a negative role in the regulation of these pathways, which suggests that it may be a useful target for drugs that are designed to promote cell growth or survival.

In conclusion, SREBF2 is a non-coding RNA molecule that has a unique structure and function. Its ability to interact with the protein p16INK4a and promote the expression of genes involved in cell apoptosis suggest that it may be a useful drug target for cancer treatment. Its involvement in the regulation of cell signaling pathways and its potential role in the regulation of cell apoptosis also make it a promising target for other diseases. Further research is needed to fully understand the unique mechanisms of SREBF2 and its potential as a drug target.

Protein Name: Sterol Regulatory Element Binding Transcription Factor 2

Functions: Precursor of the transcription factor form (Processed sterol regulatory element-binding protein 2), which is embedded in the endoplasmic reticulum membrane (PubMed:32322062). Low sterol concentrations promote processing of this form, releasing the transcription factor form that translocates into the nucleus and activates transcription of genes involved in cholesterol biosynthesis (PubMed:32322062)

The "SREBF2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SREBF2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets